ArticleBMC endocrine disorders2026
A community‑based study of platelet‑to‑white blood cell ratio and new‑onset type 2 diabetes in older adults.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThe platelet-to-white blood cell ratio (PWR) is a potential hematological indicator of dynamic changes in chronic inflammation. We aimed to investigate the association between the PWR and the risk of new-onset type 2 diabetes (T2D) in older adults.
methodsThis retrospective community-based cohort study included 7571 community-dwelling older adults without diabetes from Kunshan, Jiangsu, China, who underwent health check-ups between January 2018 and December 2023. The PWR was calculated as the platelet count divided by the white blood cell count. The primary outcome was new-onset T2D. Associations were assessed using Cox proportional hazards models to compute hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsDuring follow-up, 773 incident T2D cases occurred, and higher baseline PWR was significantly associated with a lower risk of T2D. Participants in the highest PWR quartile had a 24.0% lower risk (HR 0.760, 95% CI 0.615-0.940, P = 0.011) compared to the lowest quartile. Restricted cubic spline analysis revealed an approximately linear, inverse dose-response relationship (P overall < 0.001, P non-linear = 0.282). Subgroup and sensitivity analyses confirmed the robustness of this association.
conclusionsA higher baseline PWR is associated with a reduced risk of new-onset T2D in older adults, suggesting its potential as a simple, cost-effective inflammatory biomarker for T2D risk assessment in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.